DiaPep277

Phase 3Small molecule

DiaPep277 is one of 22 small molecule programs targeting Latent Autoimmune Diabetes in Adults. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Latent Autoimmune Diabetes in AdultsActive, not recruiting

Type 1 DiabetesActive, not recruiting

Latent Autoimmune Diabetes in AdultsPhase 2

Active, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

DiaPep277

AAndromeda Biotech Ltd.

Phase 3

4 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Glargine

Eli Lilly

Preclinical

4 6

Pitocin

RRetrophin

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Foradil

Viatris

Preclinical

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

Teplizumab

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes4 trials

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Completed·AAndromeda Biotech Ltd.·Phase 3·NCT01103284·475 enrolled

The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

Withdrawn·HHadassah Medical Organization·Phase 1/2·NCT01881958

Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Completed·AAndromeda Biotech Ltd.·Phase 3·NCT00615264·457 enrolled

Show 1 more trial

Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes

Completed·AAndromeda Biotech Ltd.·Phase 3·NCT00644501·43 enrolled

Treatment2 trials

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

Terminated·RRabin Medical Center·Phase 3·NCT01460251·11 enrolled

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

Terminated·AAndromeda Biotech Ltd.·Phase 3·NCT01898286·38 enrolled

Latent Autoimmune Diabetes in Adults1 trial

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Terminated·DDeveloGen Israel, Ltd.·Phase 2·NCT00058981·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DiaPep277. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DiaPep277 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DiaPep277. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Andromeda Biotech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAndromeda Biotech Ltd.

DiaPep277

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes4 trials

Treatment2 trials

Latent Autoimmune Diabetes in Adults1 trial

References

Drug Info

Quick Facts

Related News